Pipelines

© Getty Images

Verici Dx receives boost with Thermo Fisher licensing deal

By Isabel Cameron

Verici Dx, a company developing advanced clinical diagnostics for organ transplant, has entered into a global licensing partnership with healthcare giant Thermo Fisher to develop an assay for pre-transplant kidney testing.

© Getty Images

IO Biotech enrolls 380 Patients in phase 3 advanced melanoma trial

By Isabel Cameron

IO Biotech, a clinical-stage biopharma company developing therapeutic cancer vaccines, has completed enrollment in its phase 3 trial for IO102-IO103, in combination with KEYTRUDA (pembrolizumab), Merck’s anti-PD-1 therapy, in patients with advanced melanoma....

Sanofi invests $30m in MeiraGTx’s gene therapy pipeline

Sanofi invests $30m in MeiraGTx’s gene therapy pipeline

By Jonathan Smith

The London and New York-based gene therapy player MeiraGTx Holdings has received a $30 million investment from Sanofi in addition to potential strategic deals with the big pharma company down the road.

© Getty Images

Cancer vaccine shows promising long-term survival data

By Isabel Cameron

Ultimovacs, a clinical-stage biotech developing novel immunotherapeutic cancer vaccines, has announced ‘encouraging’ overall survival (OS) data for its phase 1 clinical trial in malignant melanoma.

© Getty Images

Kuano raises £1.8 million to accelerate quantum drug discovery

By Isabel Cameron

Kuano, a drug discovery company combining quantum mechanics with AI, has announced the close of its £1.8 million seed funding round, led by Mercia Ventures, and including ACF Investors, Ascension Ventures, o2h Ventures, Meltwind Advisory LLP, and other...

© Getty Images

New treatment for Fabry disease receives key recommendation

By Isabel Cameron

Chiesi, the biopharmaceutical and healthcare group, has announced that the National Institute for Health and Care Excellence (NICE) has recommended Elfabrio (pegunigalsidase alfa) as a treatment for Fabry disease in adults.

© Getty Images

Q&A: The potential of immuno-oncology - a view from the R&D department

By Isabel Cameron

Cancer immunotherapy, more commonly known as immuno-oncology, continues to gather momentum. As a rapidly evolving field, ongoing research and advancements are coming together to expand the number of available treatments, many of which are showing incredible...

© Getty Images

J&J’s Akeega FDA approval to heat up PARP battle

By Isabel Cameron

The FDA recently granted approval for Johnson & Johnson’s (J&J) Akeega, a novel first-in-class combination tablet treatment for adults with breast cancer gene (BRCA)-positive, metastatic castration-resistant prostate cancer (mCRPC).